Immunotherapy after lung cancer surgery for those not getting chemo
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove stage 2 or 3 non-small cell lung cancer, and the surgeon got all the cancer out.
- Your tumor has a protein called PD-L1 at a level of 1% or higher.
- You are not getting chemotherapy after surgery, either because you chose not to or your doctor said you're not healthy enough for it.
- You are at least 18 years old and have recovered from your surgery.
- Your cancer does not have an EGFR mutation or ALK rearrangement.
- You are not pregnant, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving Cemiplimab, an immunotherapy drug that helps your immune system fight cancer, before surgery to remove early stage non-small cell lung cancer. It aims to see if this approach can improve outcomes for people with small tumors that are more aggressive based on PET scan activity or cell appearance.
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
This trial tests if the immunotherapy drug cemiplimab, given before and after surgery, can help treat early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. If you have stage II or IIIA lung cancer that can be surgically removed and your tumor has PD-L1 expression of 50% or more, you may be eligible.
This trial tests a personalized chemotherapy approach for people with early-stage (stage II–IIIB) non-small cell lung cancer that can be removed with surgery. It uses the tumor's PD-L1 level (a marker that helps the immune system attack cancer) to guide treatment before surgery, aiming to improve outcomes.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.